{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:49:16Z","timestamp":1793713756160,"version":"4.6.1"},"reference-count":13,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":1584,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1097\/jto.0b013e318223c099","type":"journal-article","created":{"date-parts":[[2011,7,16]],"date-time":"2011-07-16T14:03:03Z","timestamp":1310824983000},"page":"1435-1437","source":"Crossref","is-referenced-by-count":134,"title":["A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations"],"prefix":"10.1016","volume":"6","author":[{"given":"Gregory J.","family":"Riely","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa L.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanoa","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naiyer A.","family":"Rizvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent A.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Kris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Catherine","family":"Pietanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Azzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee M.","family":"Krug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Pao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle S.","family":"Ginsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e318223c099_bib1","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1126\/science.6695174","article-title":"Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient","volume":"223","author":"Santos","year":"1984","journal-title":"Science"},{"key":"10.1097\/JTO.0b013e318223c099_bib2","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1158\/1078-0432.CCR-08-0646","article-title":"Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma","volume":"14","author":"Riely","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e318223c099_bib3","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1371\/journal.pmed.0020017","article-title":"KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med"},{"key":"10.1097\/JTO.0b013e318223c099_bib4","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nrclinonc.2009.106","article-title":"Are RAS mutations predictive markers of resistance to standard chemotherapy?","volume":"6","author":"Loriot","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1097\/JTO.0b013e318223c099_bib5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrc2109","article-title":"Hyperactive Ras in developmental disorders and cancer","volume":"7","author":"Schubbert","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1097\/JTO.0b013e318223c099_bib6","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1101\/gad.947701","article-title":"Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes","volume":"15","author":"Fisher","year":"2001","journal-title":"Genes Dev"},{"key":"10.1097\/JTO.0b013e318223c099_bib7","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/35074129","article-title":"Somatic activation of the K-ras oncogene causes early onset lung cancer in mice","volume":"410","author":"Johnson","year":"2001","journal-title":"Nature"},{"key":"10.1097\/JTO.0b013e318223c099_bib8","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1006\/bbrc.1997.7582","article-title":"The Ras antagonist S-farnesylthiosalicylic acid induces inhibition of MAPK activation","volume":"239","author":"Gana-Weisz","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1097\/JTO.0b013e318223c099_bib9","doi-asserted-by":"crossref","first-page":"14459","DOI":"10.1074\/jbc.272.22.14459","article-title":"K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors","volume":"272","author":"Whyte","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1097\/JTO.0b013e318223c099_bib10","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0076-6879(07)00432-6","article-title":"The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer","volume":"439","author":"Rotblat","year":"2008","journal-title":"Methods Enzymol"},{"key":"10.1097\/JTO.0b013e318223c099_bib11","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1158\/1535-7163.MCT-06-0706","article-title":"Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid)","volume":"6","author":"Zundelevich","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1097\/JTO.0b013e318223c099_bib12","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00280-009-1027-4","article-title":"Phase 1 first-in-human clinical study of S-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors","volume":"65","author":"Tsimberidou","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1097\/JTO.0b013e318223c099_bib13","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1200\/JCO.2005.04.3224","article-title":"Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas","volume":"24","author":"Pham","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415310753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415310753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T14:20:46Z","timestamp":1543674046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415310753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":13,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S1556086415310753"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e318223c099","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}